Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA says Trasylol is safe and effective
The US advisory committee said that Trasylol was safe and effective. Trasylol is used in coronary artery bypass graft surgery patients. Earlier in the year, the FDA had
The US advisory committee said that Trasylol was safe and effective. Trasylol is used in coronary artery bypass graft surgery patients. Earlier in the year, the FDA had
This phase II, study in the US, investigating the safety and efficacy of AV608, has enrolled 182 subjects diagnosed with social anxiety disorder. The study was initiated in
Oscient is seeking approval to use Factive for five-day treatment of community-acquired pneumonia (CAP). Factive is currently approved for the five-day treatment of acute bacterial exacerbations of chronic
The two grants complement the three year, $3 million grant the company was awarded at its inception as well as the commercial research revenues it is currently receiving.
The results could be significant for the treatment of Alzheimer’s as recent evidence suggests that disorders of insulin metabolism, such as insulin resistance and diabetes, increase the risk
Acadia reported that enrollment in the clinical trial is significantly ahead of schedule, which should enable the company to report results for the clinical trial during the first
Travatan has specifically been approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, who are intolerant of other intraocular pressure
HAE is a rare genetic disease that can be debilitating, painful and life-threatening and is characterized by local swelling in subcutaneous tissue, the gastrointestinal tract and the larynx.
The drug did not show any improvement in patients compared to placebo and failed to reach the expected results. Epix suggested the outcome may have been affected by
Exenatide is the first medicine in a new class of treatments known as incretin mimetics. If approved, this new medicine for type 2 diabetes is planned to be